Agios Pharmaceuticals announced that the Emirates Drug Establishment approved its oral pyruvate kinase activator, PYRUKYND, for adult patients with non‑transfusion‑dependent and transfusion‑dependent alpha‑ or beta‑thalassemia in the United Arab Emirates. The approval makes PYRUKYND the only medicine authorized in the UAE for this patient population, addressing a significant unmet need in a region with a high prevalence of thalassemia.
The approval is based on the global, randomized, double‑blind, placebo‑controlled ENERGIZE and ENERGIZE‑T Phase 3 trials, which demonstrated clinically meaningful improvements in hemoglobin levels and transfusion reduction in thalassemia patients. The decision follows Agios’ earlier approval in Saudi Arabia in August 2025 and is the first regulatory endorsement of PYRUKYND for thalassemia in the Gulf Cooperation Council.
The Gulf region is estimated to have approximately 70,000 individuals with thalassemia, and the UAE alone has a high carrier rate due to consanguineous marriage practices. Agios’ distribution partnership with NewBridge Pharmaceuticals, established in 2024, covers Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the UAE, positioning the company to launch PYRUKYND across the GCC quickly.
Financially, Agios reported $20 million in worldwide PYRUKYND net revenue for Q4 2025, an 86% year‑over‑year increase, and $54 million for the full year 2025. The company maintained a strong cash position of approximately $1.2 billion as of December 31 2025, providing the liquidity needed to support the new market launch.
CEO Brian Goff said, "Agios is steadfast in our dedication to advancing innovative medicines for patients with rare blood disorders." He added that the approval underscores the company’s strategy to broaden its PK activation franchise beyond the United States and Europe, leveraging its commercial infrastructure in the Middle East to capture a growing market opportunity.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.